Breakthrough in Glioblastoma Detection: Nano-Omics Powers Promising Blood Test

Researchers at the University of Manchester have unveiled a groundbreaking approach that could transform how we detect glioblastoma, the deadliest form of brain tumour in adults. This innovative method relies on analysing just two specific proteins in a patient's blood plasma to identify the cancer with over 90% accuracy, even distinguishing it from healthy individuals. Unlike traditional diagnostics that often come too late, this simple blood test holds the potential for earlier intervention, monitoring treatment response, and spotting recurrence before symptoms appear.

The study, published recently in Neuro-Oncology Advances, highlights the stability of these blood markers despite the tumour's notorious genetic heterogeneity and rapid evolution. For patients facing average survival times of just 12-18 months, this non-invasive tool could mean the difference between proactive treatment and reactive crisis management.

Understanding Glioblastoma: The Silent Killer in the Brain

Glioblastoma multiforme (GBM), often simply called glioblastoma, is a grade 4 glioma—the most aggressive primary brain cancer. It arises from glial cells, which support neurons, and infiltrates surrounding brain tissue rapidly. In the United Kingdom, around 3,200 people are diagnosed with GBM annually, contributing to the roughly 13,000 primary brain tumour cases each year. Shockingly, brain tumours claim more lives under age 40 than any other cancer, with GBM's five-year survival rate hovering at just 5%.

Symptoms like persistent headaches, seizures, cognitive changes, and neurological deficits typically emerge late, when the tumour has grown large. This delay stems from the blood-brain barrier (BBB), a protective filter that prevents most tumour molecules from entering the bloodstream, making early liquid biopsy challenging.

Current Challenges in Diagnosing and Monitoring GBM

Today, GBM diagnosis begins with magnetic resonance imaging (MRI) or computed tomography (CT) scans, which detect abnormalities but cannot confirm malignancy without a biopsy. This invasive procedure involves drilling into the skull to extract tissue, carrying risks like bleeding, infection, and further brain damage. Biopsies also provide only a snapshot, failing to capture the tumour's intra-tumoural heterogeneity—different cell populations within the same mass that evolve under therapy.

Post-treatment monitoring relies on serial MRIs every 2-3 months, but distinguishing tumour progression from treatment effects (pseudoprogression) remains tricky. Recurrence, inevitable in over 90% of cases within two years, often evades early detection, delaying adaptive therapies.

These limitations underscore the urgent need for non-invasive biomarkers. Liquid biopsies—analysing blood for tumour-derived components like circulating tumour DNA (ctDNA), proteins, or extracellular vesicles—offer promise but have underperformed in GBM due to low biomarker leakage across the BBB.

The Manchester Innovation: Nano-Omics and Dual-Marker Plasma Proteomics

Enter nano-omics, a cutting-edge nanotechnology platform pioneered at the University of Manchester. Nano-omics uses nanoparticles to enrich ultra-low-abundance proteins from minimal blood volumes (as little as 10 microlitres), enabling deep plasma proteomics—comprehensive protein profiling in blood plasma. This bridges systemic (blood) and localised (tumour) proteome changes, overcoming BBB hurdles.

Step-by-step, the process unfolds as follows:

• Sample collection: A routine blood draw yields plasma.
• Nanoparticle enrichment: Tailored nanoparticles capture GBM-specific proteins like F9 and COMP.
• Proteomic analysis: Mass spectrometry identifies and quantifies the dual-marker signature.
• Diagnostic readout: Algorithmic scoring >90% accuracy for GBM vs. controls.

The dual markers—coagulation factor IX (F9), involved in blood clotting, and cartilage oligomeric matrix protein (COMP), linked to extracellular matrix—rise dynamically with surgery, radiotherapy, and chemotherapy, mirroring tumour burden.University of Manchester announcement

Key Findings from the Study

The research demonstrated the signature's robustness across GBM subtypes, unaffected by genetic mutations like IDH-wildtype or MGMT status. It tracked treatment responses in real-time and flagged recurrence earlier than imaging. Notably, performance held post-recurrence, a critical feat given GBM's relapse rate.

"What is remarkable about our findings is that, despite these tumours being very different in genetic make-up, and constantly evolving, the signal in the blood is stable, robust and highly informative," said lead researcher Professor Petra Hamerlik.

This preclinical validation sets the stage for clinical translation, potentially integrating into NHS workflows.

Professor Petra Hamerlik: Driving Translational Neuro-Oncology

At the helm is Professor Petra Hamerlik, The Brain Tumour Charity Chair of Translational Neuro-Oncology and brain tumour lead at the Geoffrey Jefferson Brain Research Centre. Her lab at Manchester Cancer Research Centre (MCRC) merges nanotechnology, proteomics, and oncology. Previously at Danish institutions, Hamerlik brought nano-omics expertise to Manchester, funded by a £1.35m charity grant.

Manchester's ecosystem—home to CRUK Manchester Institute and MCRC—fosters such breakthroughs. For those inspired by this work, opportunities abound in research jobs across UK universities, where interdisciplinary teams tackle cancer challenges.

Funding, Collaborations, and UK Research Landscape

Co-funded by The Brain Tumour Charity (£1.35m for Hamerlik's chair), Danish Cancer Society, and Novo Nordisk Foundation, the study exemplifies public-philanthropic partnerships. Collaborators include Danish teams, amplifying Manchester's global reach.Brain Tumour Charity profile

UK higher education leads in brain cancer research, with centres like those at Cambridge, Oxford, and Edinburgh complementing Manchester's efforts. Government funding via UKRI and charities drives innovation, positioning universities as hubs for clinician-scientists.

Patient Impact: From Anxiety to Empowerment

For the 35 daily UK brain tumour diagnoses, late detection breeds anxiety. Hamerlik notes: "Late detection is among the contributing factors to poor outcomes and a source of anxiety our patients face." A blood test could screen high-risk groups—like those with seizures or headaches—prompting timely MRIs.

Real-world cases illustrate urgency: consider patients like those donating blood for validation, turning personal stakes into collective progress. Dr Simon Newman of the charity adds: "Early and accurate diagnosis is absolutely critical... This research marks a significant step."

Broader NHS integration could reduce biopsy needs, easing burdens on patients and systems.

Next Steps: Validation to Clinical Reality

Ongoing validation uses UK patient donations. Future phases: larger cohorts, prospective trials, FDA/EMA approval. Complementary efforts, like Hamerlik's tear-fluid biomarkers, diversify options.

Challenges remain: scaling nano-omics for routine labs, cost-effectiveness, false positives. Yet, parallels in other cancers (e.g., ctDNA for lung) bode well.

Photo by Michael D Beckwith on Unsplash

Future Outlook: Revolutionising Brain Cancer Care in UK Higher Education

This Manchester-led advance signals a paradigm shift. UK universities, via hubs like MCRC, are pivotal in translating lab discoveries to clinics. Aspiring academics can contribute through career advice and lecturer jobs.

Check professor ratings on Rate My Professor or explore higher ed jobs. The road ahead promises earlier detections, personalised therapies, and better survival—fuelled by relentless university research.